Dynavax Appoints Scientific Advisory Board to Support its Oncology and Vaccine Programs
June 28 2018 - 6:30AM
Dynavax Technologies Corporation (NASDAQ:DVAX) today announced the
formation of a six-member Scientific Advisory Board with
significant experience in research, development, and
commercialization in the fields of oncology and immunology.
Scientific Advisory Board Members
- Dennis Carson, M.D. - Director Emeritus, UC San Diego
Moores Cancer Center; Professor Emeritus of Medicine, Division of
Rheumatology, Allergy, and Immunology
- Laura Q.M. Chow, M.D. - Professor of Medicine in the Division
of Medical Oncology at the University of Washington
- Miriam Merad, M.D., Ph.D. - Mount Sinai Chair professor in
Cancer Immunology and the Director of the Precision Immunology
Institute at Mount Sinai School of Medicine in New York
- Drew M. Pardoll, M.D., Ph.D. - Abeloff Professor of Oncology,
Medicine, Pathology and Molecular Biology and Genetics at the Johns
Hopkins University, School of Medicine
- Stanley A. Plotkin, M.D. - Emeritus Professor of the University
of Pennsylvania and Adjunct Professor of the Johns Hopkins
University
- E. John Wherry, Ph.D. - Chair of the Department of Systems
Pharmacology and Translational Therapeutics (beginning July 1,
2018), and the Richard and Barbara Schiffrin President's
Distinguished Professor of Microbiology in the Perelman School of
Medicine and Director of the UPenn Institute for Immunology
“We are excited to have assembled a Scientific Advisory Board
with such great expertise,” said Robert L. Coffman, Ph.D., chief
scientific officer of Dynavax. “These six individuals have all made
significant contributions in oncology and immunology, including
discoveries that have proven to be transformative to
immuno-oncology and vaccine development. As we expand our oncology
platform and explore new vaccine opportunities, this board will be
an invaluable resource for Dynavax.”
Dennis Carson, M.D.
Dr. Carson is currently a member of the Board of Directors at
Dynavax. He was at the Scripps Clinic for 14 years, where he
advanced to become head of the clinical immunology division. While
at Scripps, he developed the drug cladribine for the effective
treatment of hairy cell leukemia, as well as two approved clinical
diagnostic agents. Dr. Carson directed the Stein Institute for
Research on Aging for thirteen years, and then the Moores Cancer
Center for eight years. During this period, he also
co-founded several biotechnology companies focused on vaccines and
oncology which successfully developed new drugs, based upon patents
from his research laboratory in the fields of DNA immunization,
nucleoside analogs, and Wnt signaling. He received his M.D.
from Columbia University and his B.A. from Haverford College. Dr.
Carson completed his residency in internal medicine and a
postdoctoral fellowship at the University of California, San
Diego.
Laura Q.M. Chow, M.D.
Dr. Chow serves as the Associate Director of the Phase I
Developmental Therapeutics Program and as an Attending Medical
Oncologist at the Seattle Cancer Care Alliance. She has been
at the University of Washington since 2010 and has been recently
promoted to full Professor and is currently an Associate Member of
Clinical Research at the Fred Hutchinson Cancer Research
Center. Her clinical expertise is in head and neck cancers
(including thyroid cancer), and lung cancers with a research focus
on immunotherapy, novel therapeutics and early phase clinical
trials. She has run, as the principal investigator, more than 35
clinical trials in both the phase I and thoracic head and neck
cancer programs and has published close to 70 peer-reviewed
publications. She teaches and presents nationally and
internationally on immune-checkpoint inhibitors in lung cancer and
head and neck cancers, immuno-oncology drug development and
clinical trial design. Dr. Chow earned her M.D. at the
University of British Columbia.
Miriam Merad, M.D., Ph.D.
Dr. Merad began at Mount Sinai in 2004, and was promoted to the
rank of Associate Professor with Tenure in 2007 and to Full
Professor in 2010. In 2014, she obtained an Endowed Chair in Cancer
Immunology. Dr. Merad’s laboratory studies the contribution of
macrophages and dendritic cells to cancer and inflammatory disease
in mice and humans. Dr. Merad’s pioneering work mapping the
regulatory network of dendritic cells (DCs) resulted in
identification of a lineage of DC, the CD103+ DC, that is now
considered a key target to improve antiviral and antitumor
immunity. These insights, along with other significant
discoveries, are now being used to develop novel macrophage and
dendritic cell-specific targets for the treatment of cancer and
inflammatory diseases. She has authored more than 160 primary
papers and reviews in high profile journals. Dr. Merad receives
funding from the National Institutes of Health (NIH) for her
research on innate immunity and their contribution to human
disease. Dr. Merad obtained her MD at the University of Algiers,
Algeria. She did her residency in Hematology and Oncology in Paris,
France and obtained her PhD in immunology in collaboration between
Stanford University and University of Paris VII.
Drew M. Pardoll, M.D., Ph.D.
Dr. Pardoll is the Director of the Bloomberg~Kimmel Institute
for Cancer Immunotherapy and Director of the Cancer Immunology
Program at the Sidney Kimmel Comprehensive Cancer Center at Johns
Hopkins. He joined the departments of oncology and medicine
at Johns Hopkins University in 1988. Dr. Pardoll has published over
300 papers as well as over 20 book chapters on the subject of T
cell immunology and cancer vaccines. He has served on the
editorial board of the Journal of the National Cancer Institute and
Cancer Cell, and has served as a member of scientific
advisory boards for the Cancer Research Institute, the University
of Pennsylvania Human Gene Therapy Gene Institute, the Biologic
Resources Branch of the National Cancer Institute, the Harvard-Dana
Farber Cancer Center, the American Association of Clinical Oncology
and the American Association of Cancer Research, along with several
successful biotech companies. He has made a number of advances in
Cellular Immunology, including the discovery of gamma - delta T
cells, NKT cells and interferon-producing killer dendritic
cells. Over the past two decades, Dr. Pardoll has studied
molecular aspects of dendritic cell biology and immune regulation,
particularly related to mechanisms by which cancer cells evade
elimination by the immune system. He is an inventor of a number of
immunotherapies, including GVAX cancer vaccines and Listeria
monocytogenes based cancer vaccines. Dr. Pardoll discovered one of
the two ligands for the PD-1 inhibitory receptor and leads the
Hopkins cancer immunology program that developed PD-1
pathway-targeted antibodies, demonstrating their clinical activity
in multiple cancer types. Dr. Pardoll attended Johns Hopkins
University where he earned his M.D., Ph.D., in 1982 and completed
his Medical Residency and Oncology Fellowship in 1985.
Stanley A. Plotkin, M.D.
Prior to his current roles, Dr. Plotkin was Professor of
Pediatrics and Microbiology at UPenn and Professor of Virology at
the Wistar Institute, while also serving as Director of Infectious
Diseases and Senior Physician at the Children’s Hospital of
Philadelphia. He also served as a member of the Board of Directors
at Dynavax until March 2018. In 1991, Dr. Plotkin left the
University to join the vaccine manufacturer,
Pasteur-Mérieux-Connaught (now called Sanofi Pasteur), where he
served as Medical and Scientific Director. He has been chairman of
the Infectious Diseases Committee and the AIDS Task Force of the
American Academy of Pediatrics, liaison member of the Advisory
Committee on Immunization Practices and Chairman of the
Microbiology and Infectious Diseases Research Committee of the
National Institutes of Health. He developed the rubella vaccine now
in standard use, is co-developer of a rotavirus vaccine and has
worked extensively on the development and application of other
vaccines including polio, rabies, varicella, and cytomegalovirus.
He earned his bachelor's degree from New York University and his MD
at SUNY Downstate Medical Center. He received his GME from the
School of Medicine, University of Pennsylvania.
E. John Wherry, Ph.D.
Dr. Wherry was appointed Assistant Professor in 2005 in the
Immunology Program at The Wistar Institute and then joined the
Department of Microbiology in the University of Pennsylvania’s
Perelman School of Medicine in 2010. Dr. Wherry’s research has
focused on pioneering work to define the cellular and molecular
nature of Immune Exhaustion - or failure of normal immune system
function – in chronic infection and cancer. His work helped
identify the role of the “checkpoint” molecule PD-1 and the ability
to block this pathway and reinvigorate the immune function from
exhausted T cells. He also has identified novel combinations of
immune treatments including one of the first to demonstrate the
efficacy of co-inhibitory receptor blockade that may be future
therapeutics for cancer and infections. Dr. Wherry received
his Ph.D. at Thomas Jefferson University in 2000 then did
postdoctoral research at Emory University from 2000-2004.
About DynavaxDynavax is a fully-integrated
biopharmaceutical company focused on leveraging the power of the
body's innate and adaptive immune responses through toll-like
receptor (TLR) stimulation. Dynavax discovers and develops novel
vaccines and immuno-oncology therapeutics. The Company’s first
commercial product, HEPLISAV-B® [Hepatitis B Vaccine (Recombinant),
Adjuvanted], was approved by the United States Food and Drug
Administration in November 2017 for prevention of infection caused
by all known subtypes of hepatitis B virus in adults age 18 years
and older. Dynavax's lead immunotherapy product, SD-101, is an
investigational cancer immunotherapeutic currently being evaluated
in Phase 1/2 studies and its second cancer immunotherapeutic,
DV281, is in Phase 1 development. For more information, visit
www.dynavax.com.
US-18-01-00127
|
|
Contact: David BurkeDirector, IR & Corporate
Communications510.665.7269dburke@dynavax.com |
Media
Contact:Rachel St. MartinW2O wcg 646.894.5757
rstmartin@w2ogroup.com |
|
|
Dynavax Technologies (NASDAQ:DVAX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Dynavax Technologies (NASDAQ:DVAX)
Historical Stock Chart
From Apr 2023 to Apr 2024